{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T04:54:08Z","timestamp":1648529648796},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,2,22]],"date-time":"2015-02-22T00:00:00Z","timestamp":1424563200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s00108-014-3598-3","type":"journal-article","created":{"date-parts":[[2015,2,20]],"date-time":"2015-02-20T08:37:38Z","timestamp":1424421458000},"page":"364-373","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Myelodysplastische Syndrome"],"prefix":"10.1007","volume":"56","author":[{"given":"F.","family":"Thol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Heuser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ganser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,2,22]]},"reference":[{"key":"3598_CR1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1182\/asheducation-2011.1.84","volume":"2011","author":"Niemeyer","year":"2011","unstructured":"Niemeyer CM, Baumann I (2011) Classification of childhood aplastic anemia and myelodysplastic syndrome. Hematology Am Soc Hematol Educ Program 2011:84\u201389","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"3598_CR2","first-page":"71","volume":"83","author":"Aul","year":"1998","unstructured":"Aul C, Bowen DT, Yoshida Y (1998) Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica 83(1):71\u201386","journal-title":"Haematologica"},{"key":"3598_CR3","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood-2013-03-492884","volume":"122","author":"Malcovati","year":"2013","unstructured":"Malcovati L, Hellstrom-Lindberg E, Bowen D et\u00a0al (2013) Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 122(17):2943\u20132964","journal-title":"Blood"},{"key":"3598_CR4","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1038\/sj.leu.2403945","volume":"19","author":"Strom","year":"2005","unstructured":"Strom SS, Gu Y, Gruschkus SK et\u00a0al (2005) Risk factors of myelodysplastic syndromes: a case-control study. Leukemia 19(11):1912\u20131918","journal-title":"Leukemia"},{"key":"3598_CR5","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","volume":"150","author":"Welch","year":"2012","unstructured":"Welch JS, Ley TJ, Link DC et\u00a0al (2012) The origin and evolution of mutations in acute myeloid leukemia. Cell 150(2):264\u2013278","journal-title":"Cell"},{"key":"3598_CR6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2141.1995.tb05310.x","volume":"91","author":"Enright","year":"1995","unstructured":"Enright H, Jacob HS, Vercellotti G et\u00a0al (1995) Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. Br J Haematol 91(2):403\u2013408","journal-title":"Br J Haematol"},{"key":"3598_CR7","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3109\/10428194.2011.618235","volume":"53","author":"Schlegelberger","year":"2012","unstructured":"Schlegelberger B, Gohring G, Thol F, Heuser\u00a0M (2012) Update on cytogenetic and molecular changes in myelodysplastic syndromes. Leuk Lymphoma 53(4):525\u2013536","journal-title":"Leuk Lymphoma"},{"key":"3598_CR8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nature06494","volume":"451","author":"Ebert","year":"2008","unstructured":"Ebert BL, Pretz J, Bosco J et\u00a0al (2008) Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 451(7176):335\u2013339","journal-title":"Nature"},{"key":"3598_CR9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nm.2054","volume":"16","author":"Starczynowski","year":"2010","unstructured":"Starczynowski DT, Kuchenbauer F, Argiropoulos B et\u00a0al (2010) Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med 16(1):49\u201358","journal-title":"Nat Med"},{"key":"3598_CR10","doi-asserted-by":"crossref","unstructured":"Bejar R, Stevenson K, Abdel-Wahab O et\u00a0al (2011) Clinical effect of point mutations in myelodysplastic syndromes. N\u00a0Engl J Med 364(26):2496\u20132506","DOI":"10.1056\/NEJMoa1013343"},{"key":"3598_CR11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","volume":"28","author":"Haferlach","year":"2014","unstructured":"Haferlach T, Nagata Y, Grossmann V et\u00a0al (2014) Landscape of genetic lesions in 944\u00a0patients with myelodysplastic syndromes. Leukemia 28(2):241\u2013247","journal-title":"Leukemia"},{"key":"3598_CR12","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","volume":"122","author":"Papaemmanuil","year":"2013","unstructured":"Papaemmanuil E, Gerstung M, Malcovati L et\u00a0al (2013) Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122(22):3616\u20133627","journal-title":"Blood"},{"key":"3598_CR13","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1182\/blood-2011-12-399337","volume":"119","author":"Thol","year":"2012","unstructured":"Thol F, Kade S, Schlarmann C et\u00a0al (2012) Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 119(15):3578\u20133584","journal-title":"Blood"},{"key":"3598_CR14","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.1182\/blood-2011-09-377275","volume":"118","author":"Malcovati","year":"2011","unstructured":"Malcovati L, Papaemmanuil E, Bowen DT et\u00a0al (2011) Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic\/myeloproliferative neoplasms. Blood 118(24):6239\u20136246","journal-title":"Blood"},{"key":"3598_CR15","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/leu.2011.321","volume":"26","author":"Damm","year":"2012","unstructured":"Damm F, Thol F, Kosmider O et\u00a0al (2012) SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications. Leukemia 26(5):1137\u20131140","journal-title":"Leukemia"},{"key":"3598_CR16","doi-asserted-by":"crossref","unstructured":"Papaemmanuil E, Cazzola M, Boultwood J et\u00a0al (2011) Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N\u00a0Engl J Med 365(15):1384\u20131395","DOI":"10.1056\/NEJMoa1103283"},{"key":"3598_CR17","doi-asserted-by":"crossref","unstructured":"Thol F, Friesen I, Damm F et\u00a0al (2011) Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J\u00a0Clin Oncol 29(18):2499\u20132506","DOI":"10.1200\/JCO.2010.33.4938"},{"key":"3598_CR18","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.3324\/haematol.2011.045559","volume":"96","author":"Thol","year":"2011","unstructured":"Thol F, Winschel C, Ludeking A et\u00a0al (2011) Rare occurrence of DNMT3A mutations in myelodysplastic syndromes. Haematologica 96(12):1870\u20131873","journal-title":"Haematologica"},{"key":"3598_CR19","doi-asserted-by":"crossref","unstructured":"Jadersten M, Saft L, Smith A et\u00a0al (2011) TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J\u00a0Clin Oncol 29(15):1971\u20131979","DOI":"10.1200\/JCO.2010.31.8576"},{"key":"3598_CR20","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"Greenberg","year":"1997","unstructured":"Greenberg P, Cox C, LeBeau MM et\u00a0al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89(6):2079\u20132088","journal-title":"Blood"},{"key":"3598_CR21","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J et\u00a0al (2012) Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes. Blood 120(12):2454\u20132465","journal-title":"Blood"},{"key":"3598_CR22","doi-asserted-by":"crossref","unstructured":"Malcovati L, Germing U, Kuendgen A et\u00a0al (2007) Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J\u00a0Clin Oncol 25(23):3503\u20133510","DOI":"10.1200\/JCO.2006.08.5696"},{"key":"3598_CR23","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3324\/haematol.2012.067892","volume":"98","author":"Deschler","year":"2013","unstructured":"Deschler B, Ihorst G, Platzbecker U et\u00a0al (2013) Parameters detected by geriatric and quality of life assessment in 195\u00a0older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. Haematologica 98(2):208\u2013216","journal-title":"Haematologica"},{"key":"3598_CR24","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1046\/j.1365-2141.2003.04153.x","volume":"120","author":"Hellstrom-Lindberg","year":"2003","unstructured":"Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G et\u00a0al (2003) A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin \u2009+ \u2009granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 120(6):1037\u20131046","journal-title":"Br J Haematol"},{"key":"3598_CR25","doi-asserted-by":"crossref","unstructured":"Passweg JR, Giagounidis AA, Simcock M et\u00a0al (2011) Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase\u00a0III trial comparing antithymocyte globulin plus cyclosporine with best supportive care \u2013 SAKK\u00a033\/99. J\u00a0Clin Oncol 29(3):303\u2013309","DOI":"10.1200\/JCO.2010.31.2686"},{"key":"3598_CR26","doi-asserted-by":"crossref","unstructured":"List A, Dewald G, Bennett J et\u00a0al (2006) Lenalidomide in the myelodysplastic syndrome with chromosome\u00a05q deletion. N\u00a0Engl J Med 355(14):1456\u20131465","DOI":"10.1056\/NEJMoa061292"},{"key":"3598_CR27","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R et\u00a0al (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106(8):2912\u20132919","journal-title":"Blood"},{"key":"3598_CR28","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.3324\/haematol.2014.106880","volume":"99","author":"Onida","year":"2014","unstructured":"Onida F, Brand R, Biezen A van et\u00a0al (2014) Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retrospective analysis of the European Society for Blood and Marrow Transplantation-Chronic Malignancies Working Party. Haematologica 99(10):1582\u20131590","journal-title":"Haematologica"},{"key":"3598_CR29","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","volume":"10","author":"Fenaux","year":"2009","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E et\u00a0al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase\u00a0III study. Lancet Oncol 10(3):223\u2013232","journal-title":"Lancet Oncol"},{"key":"3598_CR30","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1182\/blood-2014-06-582809","volume":"124","author":"Bejar","year":"2014","unstructured":"Bejar R, Lord A, Stevenson K et\u00a0al (2014) TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood 124(17):2705\u20132712","journal-title":"Blood"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-014-3598-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-014-3598-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-014-3598-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,30]],"date-time":"2020-08-30T05:07:37Z","timestamp":1598764057000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-014-3598-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,22]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["3598"],"URL":"https:\/\/doi.org\/10.1007\/s00108-014-3598-3","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,22]]}}}